Exact Sciences (EXAS) PT Raised to $38 at BofA/Merrill Lynch; 'Evidence Counters Bear Thesis on Commercial Rates'
Tweet Send to a Friend
BofA/Merrill Lynch raised its price target on Exact Sciences (NASDAQ: EXAS) to $38.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
